Relay Therapeutics, Inc. cotiza a 17.88 USD y tiene una capitalización bursátil de $3.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-2608, a pan-mutant and isofor…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.41 | $-0.41 | $-0.31 |
| Estimado | $-0.40 | $-0.39 | $-0.36 | $-0.40 |
| Sorpresa | — | -5.1% | -13.9% | +22.5% |
| Métrica | RLAY | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1971.6% | -38.6% | -1933.0% |
| Net Margin | -1800.6% | -33.6% | -1767.0% |
| FCF Margin | -1536.1% | -13.9% | -1522.2% |
| ROE | -48.8% | -40.4% | -8.4% |
| ROA | -44.5% | -32.0% | -12.5% |
| Current Ratio | 22.61 | 2.84 | +19.77 |
| Debt / Equity | — | 0.28 | — |